RELMADA THERAPEUTICS, INC. Payments to Acquire Productive Assets
RELMADA THERAPEUTICS, INC. (RLMD) reported Payments to Acquire Productive Assets of $182.05 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2021-03-24
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for the quarter ending 2018-06-30 was $9.80K, a 345.05% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for the quarter ending 2017-09-30 was $2.59K, a 89.56% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for fiscal 2020 was $182.05M, a 114.56% increase from fiscal 2019.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for fiscal 2019 was $84.85M.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for fiscal 2018 was $12.39K, a 75.06% decline from fiscal 2017.
- RELMADA THERAPEUTICS, INC. payments to acquire productive assets for fiscal 2017 was $49.69K, a 91.16% decline from fiscal 2016.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month | Payments to Acquire Productive Assets 115 month | Payments to Acquire Productive Assets 118 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $182.05M 10-K · filed 2021-03-24 | |||||
| 2019-12-31 | $84.85M 10-K · filed 2021-03-24 | $84.85M 10-K · filed 2021-03-24 | ||||
| 2018-06-30 | $9.80K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $9.80K derived: sum of 2 quarters · filed 2020-03-26 | $9.80K derived: sum of 3 quarters · filed 2020-03-26 | $12.39K 10-KT · filed 2020-03-26 | ||
| 2018-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2019-05-15 | $2.59K 10-Q · filed 2019-05-15 | $4.79K derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | $2.59K 10-Q · filed 2019-02-13 | $4.79K derived: sum of 3 quarters · filed 2019-02-13 | $25.02K derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-09-30 | $2.59K 10-Q · filed 2018-11-13 | $4.79K derived: sum of 2 quarters · filed 2018-11-13 | $25.02K derived: sum of 3 quarters · filed 2018-11-13 | $27.45K derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-06-30 | $2.20K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28 | $22.43K derived: sum of 2 quarters · filed 2018-09-28 | $24.86K derived: sum of 3 quarters · filed 2018-09-28 | $49.69K 10-K · filed 2018-09-28 | ||
| 2017-03-31 | $20.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | $22.66K derived: sum of 2 quarters · filed 2018-05-14 | $47.49K 10-Q · filed 2018-05-14 | $70.53K derived: sum of 4 quarters · filed 2018-05-14 | ||
| 2016-12-31 | $2.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | $27.26K 10-Q · filed 2018-02-12 | $50.30K derived: sum of 3 quarters · filed 2018-02-12 | $113.41K derived: sum of 4 quarters · filed 2018-02-12 | ||
| 2016-09-30 | $24.83K 10-Q · filed 2017-11-14 | $47.87K derived: sum of 2 quarters · filed 2017-11-14 | $110.98K derived: sum of 3 quarters · filed 2017-11-14 | $585.77K derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | $23.04K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | $86.15K derived: sum of 2 quarters · filed 2017-09-28 | $560.95K derived: sum of 3 quarters · filed 2017-09-28 | $562.26K 10-K · filed 2017-09-28 | ||
| 2016-03-31 | $63.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | $537.90K derived: sum of 2 quarters · filed 2017-05-15 | $539.21K 10-Q · filed 2017-05-15 | $543.08K derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | $474.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10 | $476.11K 10-Q · filed 2017-02-10 | $479.98K derived: sum of 3 quarters · filed 2017-02-10 | $482.26K derived: sum of 4 quarters · filed 2017-02-10 | ||
| 2015-09-30 | $1.31K 10-Q · filed 2016-11-10 | $5.18K derived: sum of 2 quarters · filed 2016-11-10 | $7.47K derived: sum of 3 quarters · filed 2016-11-10 | $13.97K derived: sum of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | $3.87K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | $6.16K derived: sum of 2 quarters · filed 2016-09-09 | $12.66K derived: sum of 3 quarters · filed 2016-09-09 | $23.33K 10-K · filed 2016-09-09 | ||
| 2015-03-31 | $2.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | $8.79K derived: sum of 2 quarters · filed 2016-05-09 | $19.46K 10-Q · filed 2016-05-09 | $22.48K derived: sum of 4 quarters · filed 2016-05-09 | ||
| 2014-12-31 | $6.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | $17.17K 10-Q · filed 2016-02-05 | $20.19K derived: sum of 3 quarters · filed 2016-02-05 | $20.84K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2014-09-30 | $10.67K 10-Q · filed 2015-11-06 | $13.69K derived: sum of 2 quarters · filed 2015-11-06 | $14.34K derived: sum of 3 quarters · filed 2015-11-06 | $22.45K derived: sum of 4 quarters · filed 2015-11-06 | ||
| 2014-06-30 | $3.02K derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $3.67K 10-K · filed 2015-09-11 | $11.78K derived: sum of 3 quarters · filed 2015-09-11 | $12.54K derived: sum of 4 quarters · filed 2015-09-11 | ||
| 2014-03-31 | $649.00 8-K · filed 2014-05-27 | $8.76K derived: sum of 2 quarters · filed 2015-02-13 | $9.47K 10-Q · filed 2015-05-15 | $9.52K 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $8.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $8.87K 10-Q · filed 2015-02-13 | $8.87K 10-K · filed 2015-09-11 | $8.87K 8-K · filed 2014-05-27 | ||
| 2013-09-30 | $762.00 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |